Arrowhead Pharmaceuticals (ARWR) Competitors $36.06 -0.88 (-2.38%) Closing price 04:00 PM EasternExtended Trading$36.26 +0.20 (+0.57%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. SMMT, ASND, VTRS, RDY, ROIV, MRNA, QGEN, BBIO, ELAN, and VRNAShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Roivant Sciences (ROIV), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Roivant Sciences Moderna Qiagen BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Do institutionals and insiders have more ownership in ARWR or SMMT? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to ARWR or SMMT? In the previous week, Summit Therapeutics had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Summit Therapeutics and 11 mentions for Arrowhead Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.55 beat Arrowhead Pharmaceuticals' score of 0.41 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ARWR or SMMT more profitable? Arrowhead Pharmaceuticals' return on equity of -40.91% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -40.91% -11.62% Summit Therapeutics N/A -208.64%-181.28% Which has better valuation and earnings, ARWR or SMMT? Summit Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M1,404.41-$599.49M-$1.28-28.17Summit Therapeutics$700K24,036.50-$221.32M-$1.01-22.43 Which has more volatility & risk, ARWR or SMMT? Arrowhead Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, meaning that its share price is 213% less volatile than the S&P 500. Do analysts recommend ARWR or SMMT? Arrowhead Pharmaceuticals currently has a consensus target price of $43.14, suggesting a potential upside of 19.64%. Summit Therapeutics has a consensus target price of $31.29, suggesting a potential upside of 38.13%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78Summit Therapeutics 5 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.44 SummarySummit Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.11B$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-28.1721.3485.8427.65Price / Sales1,404.41470.58621.60138.35Price / CashN/A47.1938.3262.20Price / Book23.4210.4313.066.79Net Income-$599.49M-$52.40M$3.30B$275.88M7 Day Performance4.22%6.36%4.81%2.64%1 Month Performance30.04%16.14%9.99%9.13%1 Year Performance102.13%33.90%85.28%35.89% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.0851 of 5 stars$36.06-2.4%$43.14+19.6%+105.0%$5.11B$3.55M-28.17400Analyst ForecastSMMTSummit Therapeutics3.0947 of 5 stars$22.15+3.4%$31.29+41.2%+18.5%$16.45BN/A-21.93110Analyst ForecastASNDAscendis Pharma A/S3.0088 of 5 stars$210.83+3.3%$244.36+15.9%+59.1%$13.01B$393.54M-40.861,017News CoverageAnalyst ForecastVTRSViatris1.8437 of 5 stars$10.13-0.6%$10.40+2.7%-11.9%$11.81B$14.74B-3.4932,000Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories3.0471 of 5 stars$14.12-0.3%$16.95+20.0%-11.1%$11.79B$334.26B21.3927,811News CoverageAnalyst ForecastROIVRoivant Sciences3.4481 of 5 stars$16.26+0.6%$19.94+22.6%+42.1%$11.10B$23.23M-23.23860Trending NewsAnalyst ForecastInsider TradeMRNAModerna4.304 of 5 stars$27.54-3.3%$41.81+51.8%-52.2%$10.72B$3.24B-3.665,800Analyst ForecastQGENQiagen4.411 of 5 stars$46.99+0.4%$49.40+5.1%+12.8%$10.45B$1.98B27.765,765Analyst ForecastBBIOBridgeBio Pharma4.2012 of 5 stars$54.61+3.3%$63.94+17.1%+123.6%$10.44B$221.90M-13.35400Analyst ForecastELANElanco Animal Health2.6104 of 5 stars$20.68+0.2%$18.33-11.3%+40.6%$10.27B$4.44B24.059,000Analyst UpgradeVRNAVerona Pharma PLC American Depositary Share1.8948 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.21B$42.28M-107.9930News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Roivant Sciences Alternatives Moderna Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
